Ling Qin1, Rong Li2, Junyi Zhang1, Aimin Li1, Rongcheng Luo1. 1. Department of Cancer Center, Southern Medical University Guangzhou, Guangdong 510315, PR China ; Department of Cancer Center, Traditional Chinese Medicine-Integrated Hospital Guangzhou, Guangdong 510315, PR China. 2. Department of Cancer Center, Nanfang Hospital Guangzhou, Guangdong 510515, PR China.
Abstract
OBJECTIVES: MiR-29b has been reported to function as a tumor suppressor in a variety of cancers. However, its role in the regulation of breast cancer is controversial. MATERIALS AND METHODS: In this paper, we explored the expression of miR-29b in a cohort of 67 pairs of formalin-fixed paraffin-embedded specimens with detailed pathological and clinical characteristics, and further analyzed the effects of miR-29b on the malignant phenotype of HER-2-positive breast cancer cells and the relevant mechanisms involved. RESULTS: We found that the miR-29b expression is negatively associated with HER-2 expression in breast cancer tissues. Moreover, overexpression of miR-29b induced a complex phenotype in HER-2-positive breast cancer cells, namely an inhibition of cell proliferation, block of G1/S phase transition, induction of cell apoptosis, suppression of cell invasion in vitro, as well as inhibition on tumor growth in vivo, indicating that miR-29b functions as a tumor suppressor in HER2-positive breast cancer cells. Further bioinformatic prediction suggested that oncogene Stat3, which is an up-stream regulator of HER-2, was a target gene of miR-29b in breast cancer cells. We have shown that knocking down of Stat3 attenuated the malignant phenotype of breast cancer cells similar to overexpression of miR-29b, while restore expression of Stat3 in HER-2-positive breast cancer cells partially abolished the suppressive effects of miR-29b. CONCLUSION: Collectively, our data suggest that miR-29b could reverse the malignant phenotype of HER-2-positvie breast cancer through, at least partially, targeting Stat3 signaling pathway.
OBJECTIVES:MiR-29b has been reported to function as a tumor suppressor in a variety of cancers. However, its role in the regulation of breast cancer is controversial. MATERIALS AND METHODS: In this paper, we explored the expression of miR-29b in a cohort of 67 pairs of formalin-fixed paraffin-embedded specimens with detailed pathological and clinical characteristics, and further analyzed the effects of miR-29b on the malignant phenotype of HER-2-positive breast cancer cells and the relevant mechanisms involved. RESULTS: We found that the miR-29b expression is negatively associated with HER-2 expression in breast cancer tissues. Moreover, overexpression of miR-29b induced a complex phenotype in HER-2-positive breast cancer cells, namely an inhibition of cell proliferation, block of G1/S phase transition, induction of cell apoptosis, suppression of cell invasion in vitro, as well as inhibition on tumor growth in vivo, indicating that miR-29b functions as a tumor suppressor in HER2-positive breast cancer cells. Further bioinformatic prediction suggested that oncogene Stat3, which is an up-stream regulator of HER-2, was a target gene of miR-29b in breast cancer cells. We have shown that knocking down of Stat3 attenuated the malignant phenotype of breast cancer cells similar to overexpression of miR-29b, while restore expression of Stat3 in HER-2-positive breast cancer cells partially abolished the suppressive effects of miR-29b. CONCLUSION: Collectively, our data suggest that miR-29b could reverse the malignant phenotype of HER-2-positvie breast cancer through, at least partially, targeting Stat3 signaling pathway.
Entities:
Keywords:
HER2; Stat3 signaling pathway; breast cancer; miR-29b
Authors: Michael L Gatza; Joseph E Lucas; William T Barry; Jong Wook Kim; Quanli Wang; Matthew D Crawford; Michael B Datto; Michael Kelley; Bernard Mathey-Prevot; Anil Potti; Joseph R Nevins Journal: Proc Natl Acad Sci U S A Date: 2010-03-24 Impact factor: 11.205
Authors: D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich Journal: Science Date: 1989-05-12 Impact factor: 47.728
Authors: Jiaqing Hao; Fei Yan; Yuwen Zhang; Ashley Triplett; Ying Zhang; Debra A Schultz; Yanwen Sun; Jun Zeng; Kevin A T Silverstein; Qi Zheng; David A Bernlohr; Margot P Cleary; Nejat K Egilmez; Edward Sauter; Shujun Liu; Jill Suttles; Bing Li Journal: Cancer Res Date: 2018-02-06 Impact factor: 12.701
Authors: Armando Andres Roca Suarez; Nicolaas Van Renne; Thomas F Baumert; Joachim Lupberger Journal: PLoS Pathog Date: 2018-03-15 Impact factor: 7.464